HUTCHMED (China) Limited (HCM) Discusses Antibody Targeted Therapy Conjugates Platform and Lead Candidate HMPL-A251 in R&D Update Transcript
Source: SeekingAlpha
2025-10-31 19:36:23 ET
HUTCHMED (China) Limited (HCM) Discusses Antibody Targeted Therapy Conjugates Platform and Lead Candidate HMPL-A251 in R&D Update October 31, 2025 8:00 AM EDT...
Read the full article on Seeking Alpha
For further details see:
HUTCHMED (China) Limited (HCM) Discusses Antibody Targeted Therapy Conjugates Platform and Lead Candidate HMPL-A251 in R&D Update Transcript
HUTCHMED (China)
NASDAQ: HMDCF
HMDCF Trading
0.0% G/L:
$2.996 Last:
165 Volume:
$2.996 Open:
HMDCF Latest News
HMDCF Stock Data
$2,597,321,277
104,485,926
2.8%
28
N/A
Pharmaceuticals
Healthcare
HK
Hong Kong
